Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Stopped US FDA is streamlining the Biosimilar development. Thus, Biocon decided to terminate the study.

Conditions

• HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Interventions

• BIOLOGICAL: PERT-IJS plus trastuzumab, carboplatin and docetaxel
• BIOLOGICAL: Perjeta plus trastuzumab, carboplatin and docetaxel

Sponsor

Biocon Biologics UK Ltd